934-P: Effectiveness of a Digital, Personalized Lifestyle Program in People with Diabetes in Improving Glycemic Variability and Time in Range—An Urban Indian Real-World Study

Abstract

Background: Glycemic variability (GV) and Time in range (TIR) are evolving parameters helping people with diabetes (PwD) have better outcomes. The OneCare diabetes program offers CGM-monitored, digital personalized education through CDEs as health coaches and OneCare app for tracking patient’s behaviour. Methods: In a 3-month prospective study, enrolled PwD (n=31) were equipped with 14 days of CGM (Abbott freestyle) at the beginning and end of OneCare program. Using 96 daily glucose readings from each patient’s CGM, GV values were obtained from days 2 to 4, of the first sensor (CGM1), and days 12 to 14, of the second sensor (CGM2) ending at day 90. GV was calculated using EasyGV© software. Demographics, HbA1c and glycemic parameters were captured at time points. The health coach guided the progress through weekly calls. Results: 62 evaluable CGM tracings, were included in the study. At 90-day follow-up, HbA1c [%] had decreased by 1.9 from 8.7 (1.2) to 6.8 (0.8), weight [kg] decreased from 74.1 (12.2) to 70.6 (10.5), FPG [mg/dl] from 148.13 (55.5) to 107.5 (20). There were significant improvements seen between the CGM1 vs CGM2 of the GV metrics including %Coefficient Variation {28.52% (8.5); 25.85% (8.2); p=0.02}, Mean Average Glucose [mg/dL] {80.9 (34.4); 62.65 (32.6); (p=<.001)}, Standard deviation of blood glucose {38.76 (14.59); 32.78 (11.2); (p = .01)} and MAGE {97.78 (31.9); 85.86 (28.68) (mg/dl); (p= .04)}. Significant improvements in TIR (%) were seen on follow up {54.4 (21.8); 67.4 (20.9)}. Percentage of people achieving the target TIR (>70%) increased significantly from 25.8% to 54.8% (p<0.001). On follow-up, 60%(n=20) patients required lesser medication for diabetes control. Conclusion: PwD who participated in OneCare's CGM-assisted DSME program had definite improvements in GV, TIR along with other metabolic parameters. The results encourage a larger prospective study to validate the findings. Disclosure B.Sooragonda: None. Z.Fatema: Employee; Wellwork Technologies Private Limited, India. M.D.M: None.